- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07299019
Uno studio sull'Orelabrutinib in pazienti con sclerosi multipla secondaria progressiva
Uno studio di fase 3, randomizzato, in doppio cieco, sull'efficacia e la sicurezza che confronta Orelabrutinib con placebo in pazienti con sclerosi multipla secondaria progressiva non attiva
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
The study consists of the following periods:
- Screening Period: Up to 4 weeks.
- Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
- Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
- Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
- Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).
All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Patient and Medical Information
- Numero di telefono: 833-269-4696
- Email: clinicaltrialsinfo@zenasbio.com
Backup dei contatti dello studio
- Nome: Patient and Medical Information
- Numero di telefono: 833-269-4696
- Email: clinialtrialsinfo@zenasbio.com
Luoghi di studio
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- Reclutamento
- Southern Neurology Suite 2
-
-
-
-
Limburg
-
Overpelt, Limburg, Belgio, 3900
- Reclutamento
- MS-Netwerk Limburg - Revalidatie
-
-
-
-
-
Pleven, Bulgaria, 5800
- Reclutamento
- Avis Medica Hospital Pleven
-
-
Plovdiv
-
Plovdiv, Plovdiv, Bulgaria, 4000
- Reclutamento
- Medical Center Nevrocentrum
-
-
Sofia
-
Sofia, Sofia, Bulgaria, 1680
- Reclutamento
- Diagnostic and Consultative Center Convex
-
Sofia, Sofia, Bulgaria, 1510
- Reclutamento
- Medical Center Hera EOOD
-
-
Tarnovo
-
Veliko Tarnovo, Tarnovo, Bulgaria, 5000
- Reclutamento
- Medical Center Medica Plus OOD
-
-
-
-
-
Choceň, Cechia, 56501
- Reclutamento
- NEUROHK, s.r.o.
-
Jihlava, Cechia, 58601
- Reclutamento
- Regional Hospital Jihlava
-
-
-
-
-
Zagreb, Croazia, 10 000
- Reclutamento
- Klinicki Bolnicki Centar Zagreb-Rebro
-
-
-
-
Harju
-
Tallinn, Harju, Estonia, 10617
- Reclutamento
- Astra clinic (Clinic4U)
-
-
-
-
Gard
-
Nîmes, Gard, Francia, 30029
- Reclutamento
- Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
-
-
-
-
-
Tbilisi, Georgia, 0114
- Reclutamento
- LTD Pineo Medical Ecosystem
-
Tbilisi, Georgia, 0186
- Reclutamento
- Raymann, LLC
-
Tbilisi, Georgia, 0159
- Reclutamento
- NNLE Jo Ann University Hospital
-
Tbilisi, Georgia, 0186
- Reclutamento
- Caucasus Medical Center Ltd
-
-
K'alak'i T'bilisi
-
Tbilisi, K'alak'i T'bilisi, Georgia, 0114
- Reclutamento
- JSC Curatio
-
-
Saburtalo
-
Tbilisi, Saburtalo, Georgia, 0160
- Reclutamento
- MD Georgia Staff Physician MediClub Georgia
-
-
-
-
Hesse
-
Bad Homburg, Hesse, Germania, 61348
- Reclutamento
- Zentrum fur klinische Forschung Dr.Scholl GmbH
-
-
-
-
Athens
-
Cholargós, Athens, Grecia, 15562
- Reclutamento
- Metropolitan General Hospital
-
-
Attica
-
Athens, Attica, Grecia, 11526
- Reclutamento
- Errikos Dunant Hospital
-
-
-
-
Chieti
-
Chieti, Chieti, Italia, 66100
- Reclutamento
- University G. D'Annunzio of Chieti-Pescara
-
-
Isernia/Molise
-
Pozzilli, Isernia/Molise, Italia, 86077
- Reclutamento
- IRCCS Istituto Neurologico Mediterraneo Neuromed
-
-
-
-
Kauno
-
Kaunas, Kauno, Lituania, 50161
- Reclutamento
- Hospital of Lithuanian University of Health Sciences
-
-
-
-
-
Lublin, Polonia, 20-064
- Reclutamento
- Galen Clinic
-
Poznan, Polonia, 15-540
- Reclutamento
- Prywatna Lecznica Certus Sp. z o.o.
-
Szczecin, Polonia, 70-111
- Reclutamento
- EUROMEDIS Osrodek Badan Klinicznych
-
Żory, Polonia, 44-240
- Reclutamento
- Centrum Medyczne ProNeuro Żory
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polonia, 85-605
- Reclutamento
- Centrum Medyczne INTERCOR Sp. z o.o.
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polonia, 20-601
- Reclutamento
- Malva Trials
-
Lublin, Lublin Voivodeship, Polonia, 20-064
- Reclutamento
- Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.
-
Lublin, Lublin Voivodeship, Polonia, 20-064
- Reclutamento
- NZOZ Neuromed M. i M. Nastaj Sp.P
-
-
Lubusz Voivodeship
-
Nowa Sól, Lubusz Voivodeship, Polonia, 67-100
- Reclutamento
- Twoja Przychodnia Centrum Medyczne Nowa Sól
-
-
Mazovian
-
Warsaw, Mazovian, Polonia, 02-172
- Reclutamento
- MTZ Clinical Researcz Powered by pratia
-
-
Rzeszów
-
Rzeszów, Rzeszów, Polonia, 35-323
- Reclutamento
- Nmedis sp. z o.o.
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polonia, 40-081
- Reclutamento
- Centrum Medyczne Pratia Katowice
-
Katowice, Silesian Voivodeship, Polonia, 40-571
- Reclutamento
- MA-LEK Clinical Sp. z o.o.
-
Katowice, Silesian Voivodeship, Polonia, 40-584
- Reclutamento
- NZOZ Novo Med
-
-
Upper Silesia
-
Katowice, Upper Silesia, Polonia, 40-686
- Reclutamento
- Neuro Medic Clinic
-
-
Wielkopolska
-
Poznan, Wielkopolska, Polonia, 61-853
- Reclutamento
- Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy
-
Poznan, Wielkopolska, Polonia, 60-324
- Reclutamento
- Twoja Przychodnia PCM
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polonia, 91-743
- Reclutamento
- PRO SALUS Sp. z o.o. sp.k.
-
Lodz, Łódź Voivodeship, Polonia, 90-324
- Reclutamento
- Centrum Neurologii Krzysztof Selmaj
-
-
-
-
-
Guaynabo, Porto Rico, 00969
- Reclutamento
- Caribbean Center for Clinical Research
-
-
-
-
Constanța County
-
Constanța, Constanța County, Romania, 900123
- Reclutamento
- Spital Clinic CF Constanta
-
-
Suceava
-
Radauti, Suceava, Romania, 725400
- Reclutamento
- Spitalul Municipal Sf. Doctori Cosma si Damian Radauti
-
-
-
-
-
Kragujevac, Serbia, 34000
- Reclutamento
- University Clinical Centre of Kragujevac
-
Niš, Serbia, 18000
- Reclutamento
- Clinic of Neurology - Clinical Center Nis
-
-
Belgrade
-
Belgrade, Belgrade, Serbia, 11000
- Reclutamento
- University Clinical Centre of Serbia
-
-
-
-
A Coruña
-
A Coruña, A Coruña, Spagna, 15006
- Reclutamento
- Complejo Hospitalario Universitario A Coruña
-
-
Galicia
-
Vigo, Galicia, Spagna, 36312
- Reclutamento
- Hospital Alvaro Cunqueiro
-
-
Madrid
-
Madrid, Madrid, Spagna, 28007
- Reclutamento
- Hospital Gregorio Marañon
-
Majadahonda, Madrid, Spagna, 28222
- Reclutamento
- Hospital Universitario Puerta de Hierro de Majadahonda
-
-
Málaga
-
Málaga, Málaga, Spagna, 29016
- Reclutamento
- Vithas Hospital Parque San Antonio
-
-
Seville
-
Castilleja de la Cuesta, Seville, Spagna, 41950
- Reclutamento
- Hospital Vithas Nisa Sevilla
-
-
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85032
- Reclutamento
- Arizona Neuroscience Research, LLC
-
Scottsdale, Arizona, Stati Uniti, 85253
- Reclutamento
- Perseverance Research Center, LLC (PRC)
-
-
California
-
Fullerton, California, Stati Uniti, 92835
- Reclutamento
- Fullerton Neurology and Headache Center
-
Torrance, California, Stati Uniti, 90502-2006
- Reclutamento
- Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))
-
West Hollywood, California, Stati Uniti, 90048
- Reclutamento
- Regina Berkovich MD, PhD Inc
-
-
Florida
-
Boca Raton, Florida, Stati Uniti, 33487
- Reclutamento
- SFM Clinical Research, LLC
-
Bradenton, Florida, Stati Uniti, 34209
- Reclutamento
- Nova Clinical Research, LLC
-
Clearwater, Florida, Stati Uniti, 33761
- Reclutamento
- MS and Neuromuscular Center of Excellence
-
Maitland, Florida, Stati Uniti, 32751
- Reclutamento
- Neurology Associates
-
Naples, Florida, Stati Uniti, 34105
- Reclutamento
- Aqualane Clinical Research
-
Tampa, Florida, Stati Uniti, 33612
- Reclutamento
- University of South Florida Department of Neurology - MS Division
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46256
- Reclutamento
- Josephson Wallack Munshower Neurology, Pc Suite 225
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- Reclutamento
- University of Kansas Medical Center
-
Roeland Park, Kansas, Stati Uniti, 66205
- Reclutamento
- KC Research Center, PA Neurology Research Dept
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02131
- Ritirato
- Boston Clinical Trials
-
Worcester, Massachusetts, Stati Uniti, 01655
- Reclutamento
- University of Massachusetts Memorial Medical Center
-
-
Michigan
-
Rochester Hills, Michigan, Stati Uniti, 48307
- Reclutamento
- Profound Research LLC at Oakland Neurology Center
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University School of Medicine
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87131
- Reclutamento
- University Of New Mexico School Of Medicine
-
-
New York
-
New York, New York, Stati Uniti, 10029
- Reclutamento
- Mount Sinai Medical Center
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43235
- Reclutamento
- The Boster Center for Multiple Sclerosis
-
Columbus, Ohio, Stati Uniti, 43221
- Reclutamento
- The Ohio State University Wexner Medical Center (OSUWMC)
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- OMRF Multiple Sclerosis Center of Excellence
-
-
South Carolina
-
Greenville, South Carolina, Stati Uniti, 29605
- Reclutamento
- Premier Neurology
-
-
Tennessee
-
Cordova, Tennessee, Stati Uniti, 38018
- Reclutamento
- Neurology Clinic, P.C.
-
-
Texas
-
San Antonio, Texas, Stati Uniti, 78258
- Reclutamento
- Lone Star Neurology
-
Sherman, Texas, Stati Uniti, 75092
- Reclutamento
- Texas Institute for Neurological Disorders - Sherman
-
-
-
-
-
Vinnytsia, Ucraina, 21009
- Reclutamento
- Medical Clinical Investigational Center of Medical Center LLC Health Clinic
-
-
Chernivtsi Oblast
-
Chernivtsi, Chernivtsi Oblast, Ucraina, 58023
- Reclutamento
- Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital
-
-
Ivano-Frankivs'k Oblast
-
Ivano-Frankivsk, Ivano-Frankivs'k Oblast, Ucraina, 76018
- Reclutamento
- CNE City Clinical Hospital #1 of Ivano-Frankivsk council
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, Ucraina, 79000
- Reclutamento
- Limited Liability Company Medical Center Neuroclinic
-
Lviv, Lviv Oblast, Ucraina, 79029
- Reclutamento
- Limited Liability Company "Neurofocus"
-
-
-
-
-
Budapest, Ungheria, 1145
- Reclutamento
- National Institute of Clinical Neurosciences
-
Tatabánya, Ungheria, 2800
- Reclutamento
- Komarom-Esztergom Varmegyei Szent Borbala Korhaz
-
-
Komarom-Esztergom Vamegye
-
Esztergom, Komarom-Esztergom Vamegye, Ungheria, 2500
- Reclutamento
- Valeomed Kft.
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- 18 to 60 years of age, inclusive, at the time of signing the informed consent.
- Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
- Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
- Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
- Absence of clinical relapses for at least 24 months.
Exclusion Criteria:
- The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
- Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
- History or current diagnosis of other neurological disorders that may mimic MS
- History or current diagnosis of progressive multifocal leukoencephalopathy
- Active, clinically significant viral, bacterial, or fungal infection
- History of any other significant active medical condition
- History of suicidal behavior within 6 months prior to Screening
- Any prior history of malignancy
- Patients on anticoagulation, or antiplatelet therapy
- Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
- Clinically significant laboratory abnormalities at Screening.
- Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
- History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Orelabrutinib Group
Orelabrutinib PO daily |
Orelabrutinib orally |
|
Comparatore placebo: Placebo Group
Placebo PO daily |
Placebo orally |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
Lasso di tempo: Up to approximately 120 weeks
|
Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0 |
Up to approximately 120 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
12 Week CDP
Lasso di tempo: Up to approximately 120 weeks
|
Time to onset of CDP events on EDSS, confirmed over at least 12 weeks |
Up to approximately 120 weeks
|
|
T2 lesions on MRI
Lasso di tempo: Up to approximately 120 weeks
|
The total number of new or enlarging T2 lesions on MRI scans of the brain |
Up to approximately 120 weeks
|
|
24-week CDP-9-hole Peg Test
Lasso di tempo: Up to approximately 120 weeks
|
Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDP-T25FWT
Lasso di tempo: Up to approximately 120 weeks
|
Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI
Lasso di tempo: Up to approximately 120 weeks
|
Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-9HPT
Lasso di tempo: Up to approximately 120 weeks
|
Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-T25FWT
Lasso di tempo: Up to approximately 120 weeks
|
Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
Symbol Digit Modalities Test
Lasso di tempo: Up to approximately 120 weeks
|
The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit |
Up to approximately 120 weeks
|
|
Annualized relapse rate
Lasso di tempo: Up to approximately 120 weeks
|
Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses |
Up to approximately 120 weeks
|
|
To evaluate the safety and tolerability of orelabrutinib
Lasso di tempo: Up to approximately 120 weeks
|
Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0); |
Up to approximately 120 weeks
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema nervoso
- Processi patologici
- Malattia cronica
- Attributi della malattia
- Malattie autoimmuni
- Malattie del sistema immunitario
- Malattie autoimmuni demielinizzanti, SNC
- Malattie autoimmuni del sistema nervoso
- Malattie demielinizzanti
- Condizioni patologiche, segni e sintomi
- Sclerosi multipla
- Sclerosi Multipla Cronica Progressiva
- Orelabrutinib
Altri numeri di identificazione dello studio
- ZB020-03-002
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .